- Home
- PENG vs NEO Comparison
PENG vs NEO Comparison
Compare PENG & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PENG | NEO |
|---|---|---|
| Founded | 1988 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Precision Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2017 | 1999 |
Fundamental Metrics
Financial Performance| Metric | PENG | NEO |
|---|---|---|
| Price | $22.01 | $11.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 10 |
| Target Price | ★ $27.50 | $12.56 |
| AVG Volume (30 Days) | 1.2M | ★ 1.9M |
| Earning Date | 01-07-2026 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $1,368,794,000.00 | $709,162,000.00 |
| Revenue This Year | $8.56 | $10.90 |
| Revenue Next Year | $15.95 | $9.88 |
| P/E Ratio | $77.07 | ★ N/A |
| Revenue Growth | ★ 16.91 | 10.10 |
| 52 Week Low | $14.20 | $4.72 |
| 52 Week High | $29.80 | $19.12 |
Technical Indicators
Market Signals| Indicator | PENG | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 59.21 | 64.51 |
| Support Level | $19.63 | $11.75 |
| Resistance Level | $22.08 | $12.26 |
| Average True Range (ATR) | 0.82 | 0.48 |
| MACD | 0.50 | 0.01 |
| Stochastic Oscillator | 96.71 | 78.01 |
Price Performance
Historical ComparisonAbout PENG Penguin Solutions Inc. Ordinary Shares
Penguin Solutions Inc is an end-to-end technology company engaged in Intelligent Platform Solutions, Integrated Memory, and Optimized LED business. Its product include Servers, software, OCP HPC & AI system, Racks and Edge. Servers include AMD-based Serves, Intel-based Servers, etc. Software products include Scyld ClusterWare, Scyld Cloud Central, etc. OCP HPC & AI Systems includes OCP Servers & Storage and etc.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.